Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 8 | 2022 | 919 | 1.930 |
Why?
|
| Vietnam | 21 | 2026 | 185 | 1.450 |
Why?
|
| Hospitalization | 6 | 2018 | 1392 | 0.940 |
Why?
|
| Hypertension | 6 | 2023 | 612 | 0.860 |
Why?
|
| Patients | 2 | 2021 | 115 | 0.780 |
Why?
|
| Clinical Laboratory Services | 1 | 2021 | 5 | 0.700 |
Why?
|
| Medical Laboratory Personnel | 1 | 2021 | 10 | 0.690 |
Why?
|
| Hospital Mortality | 5 | 2022 | 875 | 0.690 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2022 | 95 | 0.650 |
Why?
|
| Shock, Cardiogenic | 2 | 2022 | 108 | 0.650 |
Why?
|
| Quality of Life | 2 | 2024 | 1259 | 0.640 |
Why?
|
| Telemedicine | 1 | 2024 | 363 | 0.600 |
Why?
|
| Patient Education as Topic | 3 | 2023 | 481 | 0.600 |
Why?
|
| Water Pollutants, Chemical | 1 | 2019 | 43 | 0.570 |
Why?
|
| Aged | 21 | 2024 | 14945 | 0.560 |
Why?
|
| Chitosan | 1 | 2019 | 87 | 0.550 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 460 | 0.550 |
Why?
|
| Sex Factors | 5 | 2025 | 991 | 0.520 |
Why?
|
| Sample Size | 1 | 2017 | 67 | 0.520 |
Why?
|
| Hospital Administration | 2 | 2014 | 43 | 0.520 |
Why?
|
| Life Style | 1 | 2018 | 321 | 0.500 |
Why?
|
| Heart Failure | 1 | 2024 | 948 | 0.490 |
Why?
|
| African Swine Fever | 2 | 2026 | 2 | 0.490 |
Why?
|
| African Swine Fever Virus | 2 | 2026 | 2 | 0.490 |
Why?
|
| Forecasting | 1 | 2017 | 230 | 0.480 |
Why?
|
| Male | 29 | 2025 | 31014 | 0.460 |
Why?
|
| Health Behavior | 1 | 2018 | 484 | 0.450 |
Why?
|
| Healthcare Disparities | 2 | 2010 | 407 | 0.440 |
Why?
|
| Female | 29 | 2025 | 33997 | 0.440 |
Why?
|
| Patient Selection | 1 | 2017 | 483 | 0.440 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 863 | 0.430 |
Why?
|
| Humans | 45 | 2025 | 65095 | 0.410 |
Why?
|
| Developing Countries | 4 | 2023 | 87 | 0.410 |
Why?
|
| Age Factors | 4 | 2018 | 1585 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2019 | 767 | 0.390 |
Why?
|
| Middle Aged | 16 | 2025 | 18254 | 0.370 |
Why?
|
| Acute Coronary Syndrome | 2 | 2018 | 253 | 0.370 |
Why?
|
| Sex Characteristics | 1 | 2014 | 211 | 0.370 |
Why?
|
| Aedes | 4 | 2016 | 13 | 0.370 |
Why?
|
| Risk Assessment | 2 | 2017 | 2096 | 0.360 |
Why?
|
| Dengue | 4 | 2016 | 96 | 0.360 |
Why?
|
| Vibrio cholerae O1 | 3 | 2019 | 6 | 0.340 |
Why?
|
| Dengue Virus | 3 | 2015 | 99 | 0.320 |
Why?
|
| Myocardial Revascularization | 1 | 2010 | 78 | 0.310 |
Why?
|
| Surveys and Questionnaires | 6 | 2025 | 2762 | 0.310 |
Why?
|
| Outpatients | 2 | 2022 | 142 | 0.300 |
Why?
|
| Genotype | 4 | 2026 | 673 | 0.300 |
Why?
|
| Nurses | 2 | 2021 | 110 | 0.300 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 106 | 0.300 |
Why?
|
| Noncommunicable Diseases | 2 | 2019 | 18 | 0.300 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 436 | 0.290 |
Why?
|
| Transportation of Patients | 1 | 2009 | 50 | 0.290 |
Why?
|
| Heart Block | 1 | 2008 | 21 | 0.280 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 460 | 0.280 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 5606 | 0.280 |
Why?
|
| Prospective Studies | 5 | 2024 | 3306 | 0.270 |
Why?
|
| Inpatients | 1 | 2010 | 318 | 0.260 |
Why?
|
| Prognosis | 4 | 2018 | 1779 | 0.240 |
Why?
|
| Adult | 16 | 2025 | 17351 | 0.240 |
Why?
|
| Incidence | 6 | 2018 | 1418 | 0.240 |
Why?
|
| Viral Vaccines | 1 | 2026 | 56 | 0.230 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 2482 | 0.230 |
Why?
|
| Vibrio cholerae O139 | 2 | 2019 | 2 | 0.220 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2009 | 497 | 0.220 |
Why?
|
| Employment | 1 | 2025 | 132 | 0.210 |
Why?
|
| Pharmacists | 3 | 2020 | 130 | 0.200 |
Why?
|
| Evolution, Molecular | 1 | 2026 | 349 | 0.200 |
Why?
|
| Adenoma | 1 | 2023 | 70 | 0.190 |
Why?
|
| Esophagitis | 1 | 2022 | 9 | 0.190 |
Why?
|
| Risk Factors | 6 | 2018 | 5422 | 0.190 |
Why?
|
| Peptic Ulcer | 1 | 2022 | 18 | 0.190 |
Why?
|
| Stroke Volume | 1 | 2024 | 342 | 0.190 |
Why?
|
| Coronary Artery Bypass | 2 | 2018 | 292 | 0.190 |
Why?
|
| Pain Measurement | 2 | 2021 | 343 | 0.190 |
Why?
|
| Propofol | 1 | 2022 | 21 | 0.180 |
Why?
|
| Gastroesophageal Reflux | 1 | 2022 | 93 | 0.180 |
Why?
|
| Ketamine | 1 | 2022 | 39 | 0.180 |
Why?
|
| Public Health | 2 | 2021 | 186 | 0.170 |
Why?
|
| Mobile Applications | 1 | 2023 | 140 | 0.170 |
Why?
|
| Drug Hypersensitivity | 1 | 2021 | 28 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5784 | 0.170 |
Why?
|
| Blood Culture | 1 | 2020 | 8 | 0.160 |
Why?
|
| Time Factors | 4 | 2018 | 3762 | 0.160 |
Why?
|
| Cholera | 2 | 2019 | 16 | 0.160 |
Why?
|
| Dementia | 1 | 2024 | 280 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2026 | 394 | 0.150 |
Why?
|
| Frailty | 1 | 2022 | 129 | 0.150 |
Why?
|
| Pharmacy Technicians | 1 | 2019 | 1 | 0.150 |
Why?
|
| Bacteremia | 1 | 2020 | 91 | 0.150 |
Why?
|
| Videotape Recording | 1 | 2019 | 46 | 0.150 |
Why?
|
| Computers, Handheld | 1 | 2019 | 37 | 0.150 |
Why?
|
| Perception | 1 | 2020 | 181 | 0.150 |
Why?
|
| Hospitals | 1 | 2022 | 386 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 104 | 0.150 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 25 | 0.150 |
Why?
|
| Pandemics | 2 | 2023 | 675 | 0.150 |
Why?
|
| Charcoal | 1 | 2019 | 6 | 0.150 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 872 | 0.150 |
Why?
|
| Magnetic Phenomena | 1 | 2019 | 7 | 0.150 |
Why?
|
| Pharmaceutical Services | 1 | 2019 | 33 | 0.150 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 29 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 33 | 0.150 |
Why?
|
| Coffee | 1 | 2019 | 18 | 0.150 |
Why?
|
| Ions | 1 | 2019 | 54 | 0.150 |
Why?
|
| Tea | 1 | 2019 | 32 | 0.150 |
Why?
|
| Adsorption | 1 | 2019 | 87 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2021 | 364 | 0.140 |
Why?
|
| Massachusetts | 3 | 2017 | 2144 | 0.140 |
Why?
|
| Insect Vectors | 2 | 2015 | 15 | 0.140 |
Why?
|
| Warfarin | 1 | 2019 | 125 | 0.140 |
Why?
|
| Prevalence | 3 | 2022 | 1439 | 0.140 |
Why?
|
| Growth | 1 | 2018 | 23 | 0.140 |
Why?
|
| Short Bowel Syndrome | 1 | 2018 | 6 | 0.140 |
Why?
|
| Talaromyces | 1 | 2017 | 1 | 0.140 |
Why?
|
| Itraconazole | 1 | 2017 | 14 | 0.140 |
Why?
|
| Growth Disorders | 1 | 2018 | 30 | 0.140 |
Why?
|
| Minority Groups | 1 | 2019 | 141 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2019 | 199 | 0.130 |
Why?
|
| Dermatomycoses | 1 | 2017 | 18 | 0.130 |
Why?
|
| Multiple Chronic Conditions | 1 | 2018 | 39 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 464 | 0.130 |
Why?
|
| Plant Extracts | 1 | 2019 | 130 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 804 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.130 |
Why?
|
| Poverty | 1 | 2019 | 304 | 0.130 |
Why?
|
| Kinetics | 1 | 2019 | 759 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.130 |
Why?
|
| Rural Population | 1 | 2019 | 223 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2017 | 142 | 0.130 |
Why?
|
| Child Development | 1 | 2018 | 87 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2017 | 125 | 0.130 |
Why?
|
| Minisatellite Repeats | 1 | 2016 | 7 | 0.120 |
Why?
|
| Molecular Typing | 1 | 2016 | 11 | 0.120 |
Why?
|
| Mosquito Control | 1 | 2016 | 8 | 0.120 |
Why?
|
| Insect Repellents | 1 | 2016 | 3 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 261 | 0.120 |
Why?
|
| Cause of Death | 1 | 2017 | 221 | 0.120 |
Why?
|
| Genome, Viral | 2 | 2026 | 144 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 433 | 0.120 |
Why?
|
| Culture | 2 | 2016 | 82 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2019 | 1015 | 0.110 |
Why?
|
| Wolbachia | 1 | 2015 | 5 | 0.110 |
Why?
|
| Swine | 2 | 2026 | 394 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2016 | 137 | 0.110 |
Why?
|
| Income | 3 | 2021 | 169 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 526 | 0.110 |
Why?
|
| Pain | 3 | 2022 | 399 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 85 | 0.110 |
Why?
|
| Health Education | 1 | 2016 | 189 | 0.110 |
Why?
|
| Viruses | 1 | 2015 | 81 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2015 | 117 | 0.100 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 740 | 0.100 |
Why?
|
| Young Adult | 6 | 2025 | 4810 | 0.100 |
Why?
|
| Caregivers | 1 | 2016 | 293 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2012 | 754 | 0.090 |
Why?
|
| Viremia | 2 | 2026 | 46 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6859 | 0.080 |
Why?
|
| Comorbidity | 1 | 2014 | 1119 | 0.080 |
Why?
|
| Smoking Prevention | 1 | 2012 | 163 | 0.080 |
Why?
|
| South America | 1 | 2010 | 25 | 0.080 |
Why?
|
| New Zealand | 1 | 2010 | 44 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 23 | 0.080 |
Why?
|
| North America | 1 | 2010 | 114 | 0.080 |
Why?
|
| Physicians | 1 | 2016 | 477 | 0.080 |
Why?
|
| Australia | 1 | 2010 | 130 | 0.080 |
Why?
|
| Europe | 1 | 2010 | 199 | 0.080 |
Why?
|
| Rotavirus Infections | 1 | 2009 | 2 | 0.080 |
Why?
|
| Animals | 8 | 2026 | 21308 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 140 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 152 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 171 | 0.080 |
Why?
|
| Diarrhea | 1 | 2009 | 73 | 0.070 |
Why?
|
| Aspirin | 1 | 2010 | 172 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 463 | 0.070 |
Why?
|
| Phylogeny | 2 | 2026 | 388 | 0.070 |
Why?
|
| Acute Disease | 1 | 2010 | 663 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 2 | 2019 | 105 | 0.070 |
Why?
|
| Logistic Models | 2 | 2012 | 1270 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 214 | 0.070 |
Why?
|
| Inovirus | 1 | 2008 | 2 | 0.070 |
Why?
|
| Lysogeny | 1 | 2008 | 8 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 235 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 210 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 282 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 317 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2012 | 551 | 0.060 |
Why?
|
| Registries | 1 | 2010 | 913 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2010 | 528 | 0.060 |
Why?
|
| Data Collection | 2 | 2019 | 382 | 0.060 |
Why?
|
| Adolescent | 4 | 2020 | 6305 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2703 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2026 | 62 | 0.060 |
Why?
|
| Whole Genome Sequencing | 1 | 2026 | 85 | 0.060 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2025 | 41 | 0.060 |
Why?
|
| Virulence | 1 | 2026 | 199 | 0.060 |
Why?
|
| Infant | 3 | 2018 | 1691 | 0.060 |
Why?
|
| Viral Load | 1 | 2026 | 230 | 0.060 |
Why?
|
| Universities | 1 | 2025 | 168 | 0.050 |
Why?
|
| Virus Replication | 1 | 2026 | 323 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2026 | 270 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2026 | 325 | 0.050 |
Why?
|
| Molecular Epidemiology | 2 | 2016 | 31 | 0.050 |
Why?
|
| Ghana | 1 | 2023 | 14 | 0.050 |
Why?
|
| Quarantine | 1 | 2023 | 12 | 0.050 |
Why?
|
| Cathartics | 1 | 2023 | 9 | 0.050 |
Why?
|
| Kenya | 1 | 2023 | 97 | 0.050 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2022 | 22 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2023 | 97 | 0.050 |
Why?
|
| Manometry | 1 | 2022 | 28 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2022 | 74 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2018 | 1420 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2024 | 293 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2022 | 175 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 76 | 0.040 |
Why?
|
| Fentanyl | 1 | 2022 | 66 | 0.040 |
Why?
|
| Analgesics | 1 | 2022 | 102 | 0.040 |
Why?
|
| Developed Countries | 1 | 2021 | 16 | 0.040 |
Why?
|
| Penicillins | 1 | 2021 | 32 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2022 | 113 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 83 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2022 | 160 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 9 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 105 | 0.040 |
Why?
|
| Community Health Workers | 1 | 2020 | 41 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 298 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 49 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 420 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 122 | 0.040 |
Why?
|
| United States | 3 | 2018 | 8093 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2018 | 2059 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 101 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2019 | 154 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 2018 | 20 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 53 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2024 | 686 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2018 | 101 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 493 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 526 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1698 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 371 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2016 | 46 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 844 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 962 | 0.030 |
Why?
|
| Disease Vectors | 1 | 2015 | 7 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2015 | 21 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 14 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2015 | 18 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 195 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2019 | 525 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2018 | 392 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 464 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 100 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2015 | 61 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 169 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 422 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 801 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 827 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 519 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 542 | 0.030 |
Why?
|
| Longevity | 1 | 2015 | 117 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 274 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 427 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 94 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 236 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 147 | 0.020 |
Why?
|
| Rotavirus | 1 | 2009 | 11 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2009 | 57 | 0.020 |
Why?
|
| Child, Hospitalized | 1 | 2009 | 20 | 0.020 |
Why?
|
| Psychometrics | 1 | 2012 | 392 | 0.020 |
Why?
|
| Seasons | 1 | 2009 | 139 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 262 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2618 | 0.020 |
Why?
|
| Attachment Sites, Microbiological | 1 | 2008 | 4 | 0.020 |
Why?
|
| Ileum | 1 | 2008 | 21 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2009 | 180 | 0.020 |
Why?
|
| Fimbriae, Bacterial | 1 | 2008 | 20 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2009 | 266 | 0.020 |
Why?
|
| Chromosomes, Bacterial | 1 | 2008 | 43 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 111 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2374 | 0.020 |
Why?
|
| Rabbits | 1 | 2008 | 338 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 861 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 513 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 261 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 414 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 1329 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 1979 | 0.010 |
Why?
|